{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T11:57:43Z","timestamp":1768564663947,"version":"3.49.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Previous studies yielded conflicting results on the associations between vitiligo and cardiovascular diseases (CVD), and its underlying mechanisms remain unclear. This MR study aims to elucidate the underlying causal association between vitiligo and the risk of CVD, as well as the potential mediator. Using summary statistics from genome-wide association study (GWAS), we conducted a bidirectional two-sample Mendelian randomization (MR) analysis and mediation analysis to investigate the causal association between vitiligo and 13 CVD outcomes and potential mediators. The IVW method was the main MR analysis method, supplemented by MR-Egger, weighted median, and weighted mode methods. Multiple sensitivity analyses were applied to enhance the robustness of the results. Bioinformatics analysis involved Protein-Protein Interaction (PPI) network, Gene Ontology (GO) and GeneMANIA functional analysis analysis. MR analysis indicated that genetically predicted vitiligo was significantly associated with higher risk of coronary heart disease (CHD) (OR\u2009=\u20091.0199, 95% CI\u2009=\u20091.0024\u20131.0377, <jats:italic>p<\/jats:italic>\u2009=\u20090.026). There was no significant causal association between vitiligo and 12 other cardiovascular diseases. And reverse MR analysis found no causal effect of CVD on vitiligo. CCL11 was identified to partially mediate the association between vitiligo and CHD. GO and GeneMANIA suggested that CCL11 may mediate the association between vitiligo and CHD through chemokine-related functions and pathways. Our study revealed the potential causal association between vitiligo and CHD, with CCL11 as a potential mediator. Further studies are necessitated to elucidate the exact association and the mechanisms.<\/jats:p>","DOI":"10.1038\/s41598-025-95638-y","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T17:03:36Z","timestamp":1743527016000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Associations and mediators between vitiligo and cardiovascular diseases: a Mendelian randomization study"],"prefix":"10.1038","volume":"15","author":[{"given":"Xiaoyan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Pu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Pu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"issue":"10354","key":"95638_CR1","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0140-6736(22)01349-6","volume":"400","author":"N Conrad","year":"2022","unstructured":"Conrad, N. et al. Autoimmune diseases and cardiovascular risk: A population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. Lancet 400(10354), 733\u2013743 (2022).","journal-title":"Lancet"},{"issue":"11","key":"95638_CR2","first-page":"28","volume":"12","author":"ARS Ahmed","year":"2019","unstructured":"Ahmed, A. R. S., Hussein, M. S. & Mansour, A. I. Are patients with vitiligo more prone to myocardial infarction?: A case-control study. J. Clin. Aesthet. Dermatol. 12(11), 28\u201331 (2019).","journal-title":"J. Clin. Aesthet. Dermatol."},{"issue":"3","key":"95638_CR3","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/pcmr.12941","volume":"34","author":"Y Azzazi","year":"2021","unstructured":"Azzazi, Y. et al. Support for increased cardiovascular risk in non-segmental vitiligo among Egyptians: A hospital-based, case-control study. Pigment Cell. Melanoma Res. 34(3), 598\u2013604 (2021).","journal-title":"Pigment Cell. Melanoma Res."},{"issue":"2","key":"95638_CR4","doi-asserted-by":"publisher","first-page":"e14803","DOI":"10.1111\/dth.14803","volume":"34","author":"N Namazi","year":"2021","unstructured":"Namazi, N. et al. Increased risk of subclinical atherosclerosis and metabolic syndrome in patients with vitiligo: A real association or a coincidence? Dermatol. Ther. 34(2), e14803 (2021).","journal-title":"Dermatol. Ther."},{"issue":"4","key":"95638_CR5","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/jdv.12117","volume":"28","author":"M Arunachalam","year":"2014","unstructured":"Arunachalam, M. et al. Non-segmental vitiligo and psoriasis comorbidity\u2014A case-control study in Italian patients. J. Eur. Acad. Dermatol. Venereol. 28(4), 433\u2013437 (2014).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"1","key":"95638_CR6","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/j.1468-3083.2011.04392.x","volume":"27","author":"M Rodriguez-Martin","year":"2013","unstructured":"Rodriguez-Martin, M. et al. Patients with vitiligo present fewer cardiovascular risk factors: Results from a case-control study. J. Eur. Acad. Dermatol. Venereol. 27(1), 124\u2013125 (2013).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"6","key":"95638_CR7","doi-asserted-by":"publisher","first-page":"e773","DOI":"10.1111\/jdv.18936","volume":"37","author":"PC Wu","year":"2023","unstructured":"Wu, P. C. et al. Lack of association between vitiligo and major adverse cardiovascular events: A population-based cohort study. J. Eur. Acad. Dermatol. Venereol. 37(6), e773\u2013e775 (2023).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"2","key":"95638_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00403-019-01996-9","volume":"312","author":"N Gholijani","year":"2020","unstructured":"Gholijani, N., Yazdani, M. R. & Dastgheib, L. Predominant role of innate pro-inflammatory cytokines in vitiligo disease. Arch. Dermatol. Res. 312(2), 123\u2013131 (2020).","journal-title":"Arch. Dermatol. Res."},{"issue":"1","key":"95638_CR9","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.clindermatol.2017.09.016","volume":"36","author":"S Seremet","year":"2018","unstructured":"Seremet, S. & Gurel, M. S. Miscellaneous skin disease and the metabolic syndrome. Clin. Dermatol. 36(1), 94\u2013100 (2018).","journal-title":"Clin. Dermatol."},{"issue":"7139","key":"95638_CR10","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1136\/bmj.316.7139.1236","volume":"316","author":"TV Perneger","year":"1998","unstructured":"Perneger, T. V. What\u2019s wrong with bonferroni adjustments. BMJ 316(7139), 1236\u20131238 (1998).","journal-title":"BMJ"},{"issue":"4","key":"95638_CR11","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/jdi.13042","volume":"10","author":"N Katakami","year":"2019","unstructured":"Katakami, N., Matsuoka, T. A. & Shimomura, I. Clinical utility of carotid ultrasonography: Application for the management of patients with diabetes. J. Diabetes Investig. 10(4), 883\u2013898 (2019).","journal-title":"J. Diabetes Investig."},{"key":"95638_CR12","doi-asserted-by":"publisher","first-page":"105423","DOI":"10.1016\/j.ebiom.2024.105423","volume":"109","author":"A Fraczek","year":"2024","unstructured":"Fraczek, A. et al. Vitiligo is associated with an increased risk of cardiovascular diseases: A large-scale, propensity-matched, US-based retrospective study. EBioMedicine 109, 105423 (2024).","journal-title":"EBioMedicine"},{"issue":"3","key":"95638_CR13","doi-asserted-by":"publisher","first-page":"219","DOI":"10.4274\/balkanmedj.2016.1005","volume":"34","author":"H Atas","year":"2017","unstructured":"Atas, H. & Gonul, M. Increased risk of metabolic syndrome in patients with vitiligo. Balkan Med. J. 34(3), 219\u2013225 (2017).","journal-title":"Balkan Med. J."},{"issue":"Suppl 1","key":"95638_CR14","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1111\/dth.12012","volume":"25","author":"A Pietrzak","year":"2012","unstructured":"Pietrzak, A. et al. Metabolic syndrome in vitiligo. Dermatol. Ther. 25(Suppl 1), S41\u2013S43 (2012).","journal-title":"Dermatol. Ther."},{"issue":"Suppl 1","key":"95638_CR15","doi-asserted-by":"publisher","first-page":"S77","DOI":"10.1016\/j.dsx.2016.12.009","volume":"11","author":"YK Sharma","year":"2017","unstructured":"Sharma, Y. K. et al. Metabolic syndrome in vitiligo patients among a semi-urban Maharashtrian population: A case control study. Diabetes Metab. Syndr. 11(Suppl 1), S77\u2013S80 (2017).","journal-title":"Diabetes Metab. Syndr."},{"issue":"1","key":"95638_CR16","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1365-2230.2011.04142.x","volume":"37","author":"AS Karadag","year":"2012","unstructured":"Karadag, A. S. et al. Serum holotranscobalamine, vitamin B12, folic acid and homocysteine levels in patients with vitiligo. Clin. Exp. Dermatol. 37(1), 62\u201364 (2012).","journal-title":"Clin. Exp. Dermatol."},{"issue":"2","key":"95638_CR17","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.jaad.2010.08.025","volume":"64","author":"JI Silverberg","year":"2011","unstructured":"Silverberg, J. I. & Silverberg, N. B. Serum homocysteine as a biomarker of vitiligo vulgaris severity: A pilot study. J. Am. Acad. Dermatol. 64(2), 445\u2013447 (2011).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"5","key":"95638_CR18","first-page":"629","volume":"20","author":"P Kang","year":"2022","unstructured":"Kang, P. et al. Association between vitiligo and relevant components of metabolic syndrome: A systematic review and meta-analysis. J. Dtsch. Dermatol. Ges. 20(5), 629\u2013641 (2022).","journal-title":"J. Dtsch. Dermatol. Ges"},{"issue":"3","key":"95638_CR19","first-page":"268","volume":"46","author":"JL Held","year":"1990","unstructured":"Held, J. L. & Kohn, S. R. Vitiligo and pernicious anemia presenting as congestive heart failure. Cutis 46(3), 268\u2013270 (1990).","journal-title":"Cutis"},{"issue":"5","key":"95638_CR20","first-page":"499","volume":"74","author":"A Pelosio","year":"1989","unstructured":"Pelosio, A. et al. Pernicious anemia, vitiligo and positive antiglobulin test: An unusual association. Haematologica 74(5), 499\u2013501 (1989).","journal-title":"Haematologica"},{"issue":"1","key":"95638_CR21","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jaad.2003.12.031","volume":"51","author":"PE Grimes","year":"2004","unstructured":"Grimes, P. E. et al. Topical tacrolimus therapy for vitiligo: Therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J. Am. Acad. Dermatol. 51(1), 52\u201361 (2004).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"7","key":"95638_CR22","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/jid.2011.463","volume":"132","author":"JE Harris","year":"2012","unstructured":"Harris, J. E. et al. A mouse model of vitiligo with focused epidermal depigmentation requires IFN-gamma for autoreactive CD8(+) T-cell accumulation in the skin. J. Invest. Dermatol. 132(7), 1869\u20131876 (2012).","journal-title":"J. Invest. Dermatol."},{"issue":"6","key":"95638_CR23","doi-asserted-by":"publisher","first-page":"664","DOI":"10.2340\/00015555-2080","volume":"95","author":"L Yang","year":"2015","unstructured":"Yang, L. et al. Interferon-gamma inhibits melanogenesis and induces apoptosis in melanocytes: A pivotal role of CD8\u2009+\u2009Cytotoxic T lymphocytes in vitiligo. Acta Derm Venereol. 95(6), 664\u2013670 (2015).","journal-title":"Acta Derm Venereol."},{"key":"95638_CR24","doi-asserted-by":"publisher","first-page":"872458","DOI":"10.3389\/fimmu.2022.872458","volume":"13","author":"CY Ng","year":"2022","unstructured":"Ng, C. Y. et al. Skin interstitial fluid and plasma multiplex cytokine analysis reveals IFN-gamma signatures and granzyme B as useful biomarker for activity, severity and prognosis assessment in vitiligo. Front. Immunol. 13, 872458 (2022).","journal-title":"Front. Immunol."},{"issue":"3 Pt 1","key":"95638_CR25","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/jid.2011.377","volume":"132","author":"F Shi","year":"2012","unstructured":"Shi, F. & Erf, G. F. IL-21, and IL-10 co-expression in evolving autoimmune vitiligo lesions of Smyth line chickens. J. Invest. Dermatol. 132(3 Pt 1), 642\u2013649 (2012).","journal-title":"J. Invest. Dermatol."},{"issue":"5","key":"95638_CR26","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1097\/01.LAB.0000069521.42488.1B","volume":"83","author":"A Wankowicz-Kalinska","year":"2003","unstructured":"Wankowicz-Kalinska, A. et al. Immunopolarization of CD4\u2009+\u2009and CD8\u2009+\u2009T cells to type-1-like is associated with melanocyte loss in human vitiligo. Lab. Invest. 83(5), 683\u2013695 (2003).","journal-title":"Lab. Invest."},{"issue":"2","key":"95638_CR27","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1084\/jem.177.2.573","volume":"177","author":"I Iwamoto","year":"1993","unstructured":"Iwamoto, I. et al. Interferon gamma regulates antigen-induced eosinophil recruitment into the mouse airways by inhibiting the infiltration of CD4\u2009+\u2009T cells. J. Exp. Med. 177(2), 573\u2013576 (1993).","journal-title":"J. Exp. Med."},{"issue":"6","key":"95638_CR28","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1093\/intimm\/11.6.1001","volume":"11","author":"M Miyamasu","year":"1999","unstructured":"Miyamasu, M. et al. Th1-derived cytokine IFN-gamma is a potent inhibitor of eotaxin synthesis in vitro. Int. Immunol. 11(6), 1001\u20131004 (1999).","journal-title":"Int. Immunol."},{"issue":"2","key":"95638_CR29","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1159\/000065880","volume":"129","author":"K Fukuda","year":"2002","unstructured":"Fukuda, K. et al. Inhibition of eotaxin expression in human corneal fibroblasts by interferon-gamma. Int. Arch. Allergy Immunol. 129(2), 138\u2013144 (2002).","journal-title":"Int. Arch. Allergy Immunol."},{"issue":"2","key":"95638_CR30","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.bbrc.2003.12.124","volume":"314","author":"T Sato","year":"2004","unstructured":"Sato, T. et al. IFN-gamma-induced SOCS-1 regulates STAT6-dependent eotaxin production triggered by IL-4 and TNF-alpha. Biochem. Biophys. Res. Commun. 314(2), 468\u2013475 (2004).","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6","key":"95638_CR31","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1111\/bjd.14416","volume":"174","author":"XX Wang","year":"2016","unstructured":"Wang, X. X. et al. Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo. Br. J. Dermatol. 174(6), 1318\u20131326 (2016).","journal-title":"Br. J. Dermatol."},{"issue":"8","key":"95638_CR32","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1002\/eji.200323787","volume":"33","author":"G Xanthou","year":"2003","unstructured":"Xanthou, G. et al. CCR3 functional responses are regulated by both CXCR3 and its ligands CXCL9, CXCL10 and CXCL11. Eur. J. Immunol. 33(8), 2241\u20132250 (2003).","journal-title":"Eur. J. Immunol."},{"issue":"18","key":"95638_CR33","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1161\/01.CIR.102.18.2185","volume":"102","author":"KJ Haley","year":"2000","unstructured":"Haley, K. J. et al. Overexpression of eotaxin and the CCR3 receptor in human atherosclerosis: Using genomic technology to identify a potential novel pathway of vascular inflammation. Circulation 102(18), 2185\u20132189 (2000).","journal-title":"Circulation"},{"issue":"1","key":"95638_CR34","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0167-5273(01)00454-5","volume":"80","author":"E Economou","year":"2001","unstructured":"Economou, E. et al. Chemokines in patients with ischaemic heart disease and the effect of coronary angioplasty. Int. J. Cardiol. 80(1), 55\u201360 (2001).","journal-title":"Int. J. Cardiol."},{"issue":"8","key":"95638_CR35","doi-asserted-by":"publisher","first-page":"446","DOI":"10.2310\/6650.2006.06025","volume":"54","author":"J Kaehler","year":"2006","unstructured":"Kaehler, J. et al. Association between eotaxin (CCL11), C-reactive protein, and antimicrobial antibodies in patients undergoing coronary angioplasty. J. Investig Med. 54(8), 446\u2013454 (2006).","journal-title":"J. Investig Med."},{"issue":"1","key":"95638_CR36","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2005.07.002","volume":"186","author":"E Emanuele","year":"2006","unstructured":"Emanuele, E. et al. Association of plasma eotaxin levels with the presence and extent of angiographic coronary artery disease. Atherosclerosis 186(1), 140\u2013145 (2006).","journal-title":"Atherosclerosis"},{"issue":"7","key":"95638_CR37","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1161\/01.ATV.0000131654.90788.f5","volume":"24","author":"RB Kodali","year":"2004","unstructured":"Kodali, R. B. et al. CCL11 (Eotaxin) induces CCR3-dependent smooth muscle cell migration. Arterioscler. Thromb. Vasc Biol. 24(7), 1211\u20131216 (2004).","journal-title":"Arterioscler. Thromb. Vasc Biol."},{"issue":"12","key":"95638_CR38","doi-asserted-by":"publisher","first-page":"7571","DOI":"10.4049\/jimmunol.166.12.7571","volume":"166","author":"R Salcedo","year":"2001","unstructured":"Salcedo, R. et al. Eotaxin (CCL11) induces in vivo angiogenic responses by human CCR3\u2009+\u2009endothelial cells. J. Immunol. 166(12), 7571\u20137578 (2001).","journal-title":"J. Immunol."},{"issue":"11 Suppl","key":"95638_CR39","first-page":"S87","volume":"100","author":"SM Schwartz","year":"1997","unstructured":"Schwartz, S. M. Smooth muscle migration in atherosclerosis and restenosis. J. Clin. Invest. 100(11 Suppl), S87\u2013S89 (1997).","journal-title":"J. Clin. Invest."},{"key":"95638_CR40","doi-asserted-by":"crossref","unstructured":"Gencer, S. et al. Inflammatory chemokines in atherosclerosis. Cells 10(2) (2021).","DOI":"10.3390\/cells10020226"},{"issue":"2","key":"95638_CR41","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/cvr\/cvp391","volume":"86","author":"A Zernecke","year":"2010","unstructured":"Zernecke, A. & Weber, C. Chemokines in the vascular inflammatory response of atherosclerosis. Cardiovasc. Res. 86(2), 192\u2013201 (2010).","journal-title":"Cardiovasc. Res."},{"issue":"7","key":"95638_CR42","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/exd.13020","volume":"25","author":"T Buhl","year":"2016","unstructured":"Buhl, T. & Schon, M. P. Peeking into immunoregulatory effects of phototherapy. Exp. Dermatol. 25(7), 511\u2013512 (2016).","journal-title":"Exp. Dermatol."},{"issue":"4","key":"95638_CR43","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s12265-021-10189-7","volume":"15","author":"XY Li","year":"2022","unstructured":"Li, X. Y. et al. Weak UVB irradiation promotes macrophage M2 polarization and stabilizes atherosclerosis. J. Cardiovasc. Transl Res. 15(4), 855\u2013864 (2022).","journal-title":"J. Cardiovasc. Transl Res."},{"issue":"1","key":"95638_CR44","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1161\/ATVBAHA.116.308063","volume":"37","author":"N Sasaki","year":"2017","unstructured":"Sasaki, N. et al. UVB exposure prevents atherosclerosis by regulating Immunoinflammatory responses. Arterioscler. Thromb. Vasc Biol. 37(1), 66\u201374 (2017).","journal-title":"Arterioscler. Thromb. Vasc Biol."},{"issue":"1","key":"95638_CR45","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1038\/s41467-020-18147-8","volume":"11","author":"Z Song","year":"2020","unstructured":"Song, Z. et al. Clinically applicable histopathological diagnosis system for gastric cancer detection using deep learning. Nat. Commun. 11(1), 4294 (2020).","journal-title":"Nat. Commun."},{"issue":"1","key":"95638_CR46","doi-asserted-by":"publisher","first-page":"9935","DOI":"10.1038\/s41467-024-53993-w","volume":"15","author":"H Kabir","year":"2024","unstructured":"Kabir, H. et al. Automated Estimation of cementitious sorptivity via computer vision. Nat. Commun. 15(1), 9935 (2024).","journal-title":"Nat. Commun."},{"issue":"11","key":"95638_CR47","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1038\/ng.3680","volume":"48","author":"Y Jin","year":"2016","unstructured":"Jin, Y. et al. Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants. Nat. Genet. 48(11), 1418\u20131424 (2016).","journal-title":"Nat. Genet."},{"issue":"9","key":"95638_CR48","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1038\/s41590-023-01588-w","volume":"24","author":"JH Zhao","year":"2023","unstructured":"Zhao, J. H. et al. Genetics of Circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets. Nat. Immunol. 24(9), 1540\u20131551 (2023).","journal-title":"Nat. Immunol."},{"issue":"6","key":"95638_CR49","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1093\/ije\/dyx102","volume":"46","author":"FP Hartwig","year":"2017","unstructured":"Hartwig, F. P., Davey, S. G. & Bowden, J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. Int. J. Epidemiol. 46(6), 1985\u20131998 (2017).","journal-title":"Int. J. Epidemiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95638-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95638-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95638-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T16:43:53Z","timestamp":1743785033000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95638-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["95638"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-95638-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"assertion":[{"value":"7 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11110"}}